peptidoglycan Inhibitors
1 drugsAbout peptidoglycan
Peptidoglycan, or murein, is a mesh-like polymer essential to bacterial cell walls, providing structural integrity and preventing osmotic lysis. Its unique presence in bacteria makes it an attractive target for antibacterial drug development.
Peptidoglycan's critical role in bacterial survival underscores its importance in combating bacterial infections. Currently, there is no genetic evidence directly linking peptidoglycan to specific diseases.
One FDA-approved drug, BICILLIN C-R 900/300, targets peptidoglycan synthesis as a small molecule. KING PHARMS LLC is the sole company with an approved drug targeting this pathway.
Top peptidoglycan Drugs
KING PHARMS LLC is the only company with an approved drug targeting peptidoglycan.
Low competition suggests high barriers to entry or limited commercial interest in this target.
peptidoglycan Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets peptidoglycan, using small molecule modality.
The exclusive use of small molecules indicates a whitespace opportunity for alternative modalities like antibodies or peptides.
peptidoglycan Clinical Trials 2 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on peptidoglycan. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
peptidoglycan Drug Approval Timeline (1953 - 1953)
The first and most recent drug approval for peptidoglycan was BICILLIN C-R 900/300 in 1953.
The lack of recent approvals suggests a saturated market or challenges in developing new peptidoglycan-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on peptidoglycan. A trial counts if an approved drug acting on peptidoglycan is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.